| Literature DB >> 17874061 |
F vom Dorp1, S Krege, H Rübben.
Abstract
Up to now systemic therapy with curative intent is possible in only a few tumors. Concerning advanced malignant tumors in urology only testicular cancer can be cured. In metastatic urothelial cancer of the bladder this might be possible in single cases. In advanced renal cell carcinoma a recent group of new substances, so-called target-specific substances, have gained attention. In several phase III studies with sunitinib, sorafenib, and temsirolimus at least progression-free survival could be clearly prolonged. The amazing results in testicular cancer were possible by consistent performance of clinical trials. The success in treatment also is an example for interdisciplinarity. Especially in advanced stages treatment consists of two components, chemotherapy, correctly performed concerning dose and interval, followed by complete residual tumor resection.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17874061 DOI: 10.1007/s00120-007-1539-7
Source DB: PubMed Journal: Urologe A ISSN: 0340-2592 Impact factor: 0.639